leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia.
|
29530751 |
2018 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
|
29224413 |
2018 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retinoic acid receptor α (RARα) plays important roles in the progression of several cancers such as leukemia, breast cancer, and lung cancer.
|
27932034 |
2017 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In fact, the oncogenic fusion-protein (PML-RAR) typical of this leukemia contains the retinoid-nuclear-receptor RARα.
|
27419624 |
2017 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first report showing that a lncRNAs regulates autophagy and the degradation of the PML-RARA oncoprotein during the process of myeloid cell differentiation blockade, suggesting that lncRNAs may be the potential therapeutic targets for leukemia.
|
27740626 |
2017 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Established leukemia-specific predictive biomarkers for precision medicine include those genetic lesions such as BCR-ABL1 for Philadelphia-positive acute lymphoblastic leukemia and PML-RARα for acute promyelocytic leukemia.
|
28654205 |
2017 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PML-RARα is the central leukemia-initiating event in APL and is directly targeted by all-trans-RA (ATRA) as well as arsenic.
|
27089249 |
2016 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, this proliferation signature was absent from the poorly leukemogenic p50/RARA fusion model, implying a critical role for PML in the altered cell-cycle kinetics and ability to initiate leukemia.
|
26088929 |
2015 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Unphosphorylated c-Myc interacts with RARα to repress the expression of RAR targets required for differentiation, thereby aggravating leukemia malignancy.
|
22510570 |
2012 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that TRIM32 functions as one of the co-activators for RARα-mediated transcription, and thereby TRIM32 is a potential therapeutic target for developmental disorders and RA-dependent leukemias.
|
21984809 |
2011 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, at physiologic doses, PML-RARA primarily acts to increase hematopoietic progenitor self-renewal, expanding a population of cells that are susceptible to acquiring secondary mutations that cause progression to leukemia.
|
21364283 |
2011 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further analysis showed that JAK1 V658F cooperated in vivo with PML-RARA, causing a rapidly fatal leukemia in mice.
|
21436584 |
2011 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using hierarchical clustering analysis to compare acute myeloid leukemia genetic subgroups based on their similarity of septin expression changes, we found that MLL-SEPT2 and MLL-SEPT6 neoplasias cluster together apart from the remaining subgroups and that PML-RARA leukemia presents under-expression of most septin family genes.
|
19748670 |
2010 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, DNA methylation profiles segregated patients with CEBPA aberrations from other subtypes of leukemia, defined four epigenetically distinct forms of AML with NPM1 mutations, and showed that established AML1-ETO, CBFb-MYH11, and PML-RARA leukemia entities are associated with specific methylation profiles.
|
20060365 |
2010 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
By contrast, in NPM1c(+)/FLT3-ITD(-), NPM1c(+)/FLT3-ITD(+), RUNX1-RUNX1T1, and PML-RARA leukemias, bone marrow sampling is necessary every sixth, fourth, and fourth and second month, respectively.
|
19901261 |
2010 |
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study further supports the presence of preferential sites of DNA damage induced by mitoxantrone in PML and RARA genes that may underlie the propensity to develop this subtype of leukemia after exposure to this agent.
|
18650449 |
2008 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that retinoic acid also triggers growth arrest of leukemia-initiating cells (LICs) ex vivo and their clearance in PML-RARA mouse APL in vivo.
|
19029980 |
2008 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore propose that the APL fusion protein NuMA-RARalpha cooperates with RXRalpha in the development of leukemia in hCG-NuMA-RARalpha transgenic mice and suggest a novel role for RXRalpha in the pathogenesis of APL.
|
18408763 |
2008 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the effects of PML-RARalpha on C/EBPs may contribute to both the development of leukemia and the unique sensitivity of APL to tRA.
|
12393450 |
2003 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.
|
14566333 |
2003 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nearly 98% of cases of APL are associated with t(15;17) chromosomal translocation and fusion of the PML gene to that encoding RARalpha to yield an abnormal receptor with the capability of de-regulating gene expression in the haematopoietic cell, causing differentiation block and eventually the development of leukaemia.
|
12935958 |
2003 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, recent data indicate that the RARalpha-X product is also critical in determining the biological features of this leukemia.
|
12127726 |
2002 |
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In previous studies, we demonstrated that expression of a human PML-RARA complementary DNA in murine granulocyte precursor cells initiated the development of leukemia.
|
11929790 |
2002 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that while the X-RARalpha fusion gene is crucial for leukemogenesis, the presence of RARalpha-X and the inactivation of X function are critical in modulating the onset as well as the phenotype of the leukemia.
|
11358384 |
2001 |
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two features are unique to this leukemia: its remission after retinoic acid (RA) treatment through induction of blast differentiation, and the presence in the leukemic blast of fusion proteins in which the retinoic acid receptor alpha (RARalpha) fuses to distinct partners.
|
11561158 |
2001 |